Hence, downregulation of MAPK signaling by anti-EGFR antibodies, or inhibitors of EGFR, MEK, and BRAF enhances the expression of HLA-I in several types of tumors, such as lung cancer, melanoma, and head and neck squamous cell cancer (21, 22, 25, 26). The gene discussed is EGFR; the disease is lung carcinoma.